Publications

Clinical
DR Musikantow, VY Reddy, T Shaburishvili et al
J Am Coll Cardiol EP 2024.

This Research Letter presents AtriAN’s second clinical study in which 12 cardiac surgery patients, with concomitant paroxysmal AF, underwent the epicardial GP ablation treatment. No post- operative AF occurred. Patients were monitored by 24-hour Holter at 1, 3, 6 and 12 months post- procedurally. One patient recorded a short asymptomatic event at 3 months but otherwise no AF was detected in any of the patients. Two heart rate variability parameters (rMSSD and HF power) showed durable decreases, thereby providing a further indication of denervation.

Clinical
Juan Carlos Zerpa Acosta & Gurukripa N. Kowlgi
J Interv Card Electrophysiol 2024.

This is an independent Commentary discussing AtriAN’s previously published FIH study. It specifically focuses on the potential for the AtriAN treatment to be also used in open-chest cardiac surgery as a means to prophylactically treat post-operative AF (POAF). POAF is costing healthcare systems over $1 billion annually and current prevention approaches are largely unsuccessful.

Clinical
DR Musikantow, VY Reddy, I Skalsky et al
J Interv Card Electrophysiol 2023.

AtriAN’s first-in-human safety and feasibility study is presented in this article. Ganglionated plexi (GP) were ablated in 24 patients undergoing concomitant open-chest coronary artery bypass grafting (CABG). There was no study-related complications and all GP sites were successfully treated. A 20% acute extension in atrial effective refractory period was recorded.